We are commercializing eRapa™,
a novel, targeted formulation of rapamycin, to suppress the onset and recurrence of cancer. Our pipeline includes several early stage cancers or precancerous conditions.
eRapa™ is a novel formulation of rapamycin that can extend life by delaying the onset of aging-related diseases and can postpone the effects of normal aging.
Leading indications include non-muscle invasive bladder cancer, low grade prostate cancer, and Familial Adenomatous Polyposis (FAP), a rare genetic disease that leads to colon cancer for which no current therapeutics exist.